Search company, investor...



Seed VC | Alive

Total Raised


Last Raised

$900K | 35 yrs ago

About Exocell

Developer of drugs to prevent and treat complications of diabetes, such as kidney and eye disease. The products under development include EXO-226, a glycatin inhibitor, and A717, a glycation neutralizer. Many of the company's products and product development programs apply proprietary technology and discoveries relating to excess protein glycation (the binding of glucose to proteins) in diabetes. The company also develops and markets diagnostic tests and reagents that help manage diabetes, assess the efficacy of anti-diabetic treatments, and detect and monitor complications and the risk for their development.

Headquarters Location

3508 Market Street Suite 420

Philadelphia, Pennsylvania, 19104,

United States


Missing: Exocell's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Exocell's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Exocell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Exocell is included in 1 Expert Collection, including Diabetes.



1,899 items

Exocell Patents

Exocell has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Coagulation system
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Cell biology, Obesity, Biotechnology, Proteins


Application Date


Grant Date



Related Topics

Transcription factors, Cell biology, Obesity, Biotechnology, Proteins



Latest Exocell News

La start-up ExoCell réalise la station d'épuration d'Ariane 6

Aug 26, 2020

La start-up ExoCell réalise la station d'épuration d'Ariane 6 26 août 2020 Basée à Douai (Nord), la start-up ExoCell a réalisé une station d’épuration destinée à la fusée Ariane 6. Un projet d’envergure pour cette entreprise née en 2014, qui emploie une quinzaine de salariés. ExcoCell conçoit, fabrique et commercialise des équipements destinés au traitement de l’eau. La station réalisée va permettre de nettoyer, en moins de 15 jours, l’eau utilisée au décollage. La fusée partira fin 2021 de la base de lancement de Kourou, en Guyane. Après cette opération, la jeune entreprise espère prendre de l’ampleur. Pour poursuivre votre lecture, abonnez-vous. -50% sur votre abonnement

Exocell Frequently Asked Questions (FAQ)

  • Where is Exocell's headquarters?

    Exocell's headquarters is located at 3508 Market Street, Philadelphia.

  • What is Exocell's latest funding round?

    Exocell's latest funding round is Seed VC.

  • How much did Exocell raise?

    Exocell raised a total of $900K.

  • Who are the investors of Exocell?

    Investors of Exocell include Genesis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.